Search Results

You are looking at 1 - 5 of 5 items for :

  • "Risk communication" x
  • Refine by Access: All x
Clear All
Full access

Jeffrey K. Belkora, David W. Hutton, Dan H. Moore, and Laura A. Siminoff

rate would have been candidates for routine adjuvant therapy. 16 , 17 As the objective was to study risk communication and therapy choice, the authors believed that the threshold of a greater than 85% 10-year survival rate would include not only

Full access

Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman, and Hanneke W.M. van Laarhoven

. 10.3390/cancers12040834 34. Zipkin DA , Umscheid CA , Keating NL , . Evidence-based risk communication: a systematic review . Ann Intern Med 2014 ; 161 : 270 – 280 . 25133362 10.7326/M14-0295

Full access

Michael J. Hall

preventive behaviors in unaffected relatives. Although Lynch screening has been shown to be feasible, 9 , 13 its success in this country will be hindered by pervasive societal barriers to DNA testing, risk communication, and access. For instance, in the

Full access

Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel

and risk reduction behavior, risk communication). The consent document and process is explicit about sharing anonymized biospecimens with other investigators. The Registry has facilitated scholarly research created in collaboration with community

Full access

Philip E. Johnson, George Dahlman, Kirby Eng, Rekha Garg, Scott Gottlieb, James M. Hoffman, Peyton Howell, Mohammad Jahanzeb, Shirley Johnson, Emily Mackler, Mark Rubino, Brenda Sarokhan, F. Marc Stewart, Tim Tyler, Julie M. Vose, Sharon Weinstein, Edward C. Li, and Jessica DeMartino

not invested in important social sciences such as risk communication and risk mitigation. However, the success of REMS programs depends on this ability to assess and evaluate the programs. A first step would be for the FDA to define success . Is